Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Marshfield Clinic
mi
from
Marshfield, WI
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated:  12/7/2017
The Children's Hospital at Westmead
mi
from
Sydney,
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors
Status: Enrolling
Updated: 12/7/2017
The Children's Hospital at Westmead
mi
from
Sydney,
Click here to add this to my saved trials
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy
Status: Enrolling
Updated:  12/8/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy
Status: Enrolling
Updated: 12/8/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated:  12/10/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated: 12/10/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary
Status: Enrolling
Updated:  12/11/2017
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary
Status: Enrolling
Updated: 12/11/2017
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
mi
from
New Britain, CT
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
mi
from
New Britain, CT
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
University of Illinois Cancer Center
mi
from
Chicago, IL
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
University of Illinois Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Rush University Medical Center
mi
from
Chicago, IL
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Hinsdale Hematology Oncology Associates
mi
from
Hinsdale, IL
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Hinsdale Hematology Oncology Associates
mi
from
Hinsdale, IL
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
St. John's Regional Health Center
mi
from
Springfield, MO
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
St. John's Regional Health Center
mi
from
Springfield, MO
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Hulston Cancer Center at Cox Medical Center South
mi
from
Springfield, MO
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Hulston Cancer Center at Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Mount Carmel West Hospital
mi
from
Columbus, OH
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Mount Carmel West Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
Harrington Cancer Center
mi
from
Amarillo, TX
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/12/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/12/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Michiana Hematology Oncology
mi
from
Plymouth, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Michiana Hematology Oncology
mi
from
Plymouth, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Memorial Hospital of South Bend
mi
from
South Bend, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
UC Irvine Health/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
UC Irvine Health/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
University of California, San Diego
mi
from
San Diego, CA
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Colorado Gynecologic Oncology Group
mi
from
Aurora, CO
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Colorado Gynecologic Oncology Group
mi
from
Aurora, CO
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Memorial University Medical Center
mi
from
Savannah, GA
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Northwestern University
mi
from
Chicago, IL
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
IU Health La Porte Hospital
mi
from
La Porte, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
IU Health La Porte Hospital
mi
from
La Porte, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Michiana Hematology Oncology PC-Mishawaka
mi
from
Mishawaka, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Michiana Hematology Oncology PC-Mishawaka
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated:  12/13/2017
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Status: Enrolling
Updated: 12/13/2017
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Click here to add this to my saved trials